Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejectionSerial ...

PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on p ...

The kidney is now the highest on the "wanted list" of organs, with 10,000 renal failure patients waiting for transplants.

Following the deaths of five women, female patients at Kota Medical College are refusing dialysis. They demand kidney transplants, citing severe discomfort, emotional distress, and financial hardship, ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...

Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's ...

Each week, photographer Ruth Medjber asks one person to share a tale from their own life. This week, she meets kidney ...

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's commercial strategy in ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from ...

In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft ...